Compare PLAY & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAY | IFRX |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.3M | 303.4M |
| IPO Year | 2011 | 2017 |
| Metric | PLAY | IFRX |
|---|---|---|
| Price | $8.77 | $2.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $23.83 | $6.25 |
| AVG Volume (30 Days) | ★ 1.4M | 945.6K |
| Earning Date | 06-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.57 | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $54.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.30 | $0.80 |
| 52 Week High | $24.99 | $2.95 |
| Indicator | PLAY | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 54.55 |
| Support Level | N/A | $0.87 |
| Resistance Level | $10.81 | $2.57 |
| Average True Range (ATR) | 0.51 | 0.18 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 20.11 | 38.38 |
Dave & Buster's Entertainment Inc is an owner and operator of entertainment and dining venues in North America that offer experiences for both adults and families under the Dave & Buster's and Main Event brands. The company combines various forms of entertainment, including games, bowling, and watching live sports and other televised events, with a full menu of entrees and appetizers and a selection of alcoholic and non alcoholic beverages, all in one location. Its concept focuses on providing customers the opportunity to Eat, Drink, Play, and Watch, appealing to a balanced mix of adults, families, and teenagers. The company also operates internationally in the early stage as a franchisor of the Dave & Buster's brand.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.